









Markets
/
Stocks
/
nasdaq-bio
/

Bio Rad Laboratories Inc

BIO

281.345USD

-0.915-0.32%

Market hours （ET）Quotes delayed by 15 min

7.61BMarket Cap

23.86P/E TTM



Bio Rad Laboratories Inc

281.345

-0.915-0.32%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated：2025-09-16

Key Insights

The company's fundamentals are relatively weak. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite a very weak market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

24 / 207

Overall Ranking

103 / 4724

Industry

Healthcare Equipment & Supplies

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 7 analysts

Buy

Current Rating

327.333

Target Price

+16.82%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

Bio-Rad Laboratories, Inc. is engaged in developing, manufacturing, and marketing a range of products for the life science research and clinical diagnostics markets. The Company offers a range of products and systems used to separate complex chemical and biological materials and to identify, analyze and purify their components. It operates through two segments: Life Science and Clinical Diagnostics. The Life Science segment develops, manufactures, and markets instruments, systems, reagents, and consumables used for biological research, biopharmaceutical production processes, food testing regimes, and science education. Its Clinical Diagnostics segment designs, manufactures, markets and supports test systems, informatics systems, test kits and specialized quality controls that serve clinical laboratories in the global diagnostics market. These products are sold to hospital laboratories, diagnostic reference laboratories, transfusion laboratories, and physician office laboratories.

Overvalued

The company’s latest PE is 25.47, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 24.14M shares, decreasing 12.78% quarter-over-quarter.

Held by First Eagle Investment

Star Investor First Eagle Investment holds 2.52M shares of this stock.

Financial Health

Currency: USD Updated：2025-09-16

The company's current financial score is 6.44, which is lower than the Healthcare Equipment & Supplies industry's average of 7.15. Its financial status is weak, and its operating efficiency is average. Its latest quarterly revenue reached 585.40M, representing a year-over-year decrease of 4.16%, while its net profit experienced a year-over-year decrease of 83.33%.

Score

Industry at a Glance

Previous score

8.17

Change



Financials

8.28

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

7.10

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

9.18

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

8.86

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.43

Key Metrics

Free cash flow

No Data

Company Valuation

Currency: USD Updated：2025-09-16

The company’s current valuation score is 4.80, which is higher than the Healthcare Equipment & Supplies industry's average of 2.15. Its current P/E ratio is 26.42, which is -114.77% below the recent high of -3.90 and 198.10% above the recent low of -25.92.

Score

Industry at a Glance

Previous score

4.79

Change

0.79

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 24/207

No Data

Earnings Forecast

Currency: USD Updated：2025-09-16

The company’s current earnings forecast score is 7.71, which is higher than the Healthcare Equipment & Supplies industry's average of 7.66. The average price target for Bio Rad Laboratories Inc is 325.00, with a high of 409.00 and a low of 265.00.

Score

Industry at a Glance

Previous score

7.71

Change

Support & Resistance

No Data

Analyst Rating

Based on 7 analysts

Buy

Current Rating

327.333

Target Price

+16.82%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

118

Total

Median

Average

Company name

Ratings

Analysts

Bio Rad Laboratories Inc

BIO

Medtronic PLC

MDT

Stryker Corp

SYK

Abbott Laboratories

ABT

Zimmer Biomet Holdings Inc

ZBH

Dexcom Inc

DXCM

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated：2025-09-16

The company’s current price momentum score is 9.07, which is higher than the Healthcare Equipment & Supplies industry's average of 7.47. Sideways: Currently, the stock price is trading between the resistance level at 320.51 and the support level at 253.09, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.24

Change

0.17

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(2)

Neutral(4)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

-5.312

Neutral

RSI(14)

49.773

Neutral

STOCH(KDJ)(9,3,3)

23.669

Neutral

ATR(14)

8.024

High Vlolatility

CCI(14)

-88.002

Neutral

Williams %R

76.408

Sell

TRIX(12,20)

0.148

Sell

StochRSI(14)

63.819

Buy

Moving Average

Sell(2)

Neutral(0)

Buy(4)

Indicators

Value

Direction

MA5

281.124

Buy

MA10

285.486

Sell

MA20

289.465

Sell

MA50

272.673

Buy

MA100

254.557

Buy

MA200

276.745

Buy

Institutional Confidence

Currency: USD Updated：2025-09-16

The company’s current institutional recognition score is 10.00, which is higher than the Healthcare Equipment & Supplies industry's average of 7.19. The latest institutional shareholding proportion is 109.77%, representing a quarter-over-quarter increase of 3.54%. The largest institutional shareholder is First Eagle Investment, holding a total of 2.52M shares, representing 11.45% of shares outstanding, with 267.72% increase in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

First Eagle Investment Management, L.L.C.

Star Investors

2.29M

+46.49%

The Vanguard Group, Inc.

Star Investors

1.90M

-0.53%

Alice N. Schwartz Revocable Trust

1.78M

-0.18%

BlackRock Institutional Trust Company, N.A.

1.64M

-0.29%

Dimensional Fund Advisors, L.P.

877.04K

+17.55%

Schwartz (Alice N)

951.13K

+0.23%

Veritas Asset Management LLP

913.12K

-6.52%

Ariel Investments, LLC

Star Investors

724.66K

+29.28%

EARNEST Partners, LLC

599.62K

-2.98%

State Street Global Advisors (US)

694.52K

+0.63%

Risk Assessment

Currency: USD Updated：2025-09-16

The company's beta value is 0.95. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.